Elaine J Heron bought $300K of Palvella Therapeutics (PVLA)
Executed Feb 27, disclosed Mar 2, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -21.8% (delay-adjusted); from the execution session (Feb 27), -23.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Elaine J Heron (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Palvella Therapeutics, Inc. (PVLA). Across 1 priced purchase filing, the average 21-session return was -23.3% from execution and -21.8% from disclosure (delay-adjusted; derived). The largest single filing was $300K of PVLA (2,400 sh × $125.00, as filed), executed Feb 27.
Healthcare · Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→